US 12,077,517 B2
Polymorphs of a dihydroorotate dehydrogenase (DHOD) inhibitor
Stefan Sperl, Vienna (AT); Lisa Plasser, Vienna (AT); Osama Suleiman, Cambridge (GB); Christopher Daniel Scott, Cambridge (GB); Susana Del Rio Gancedo, Cambridge (GB); and Joseph Stephen Harris, Cambridge (GB)
Assigned to Panoptes Pharma GmbH, Vienna (AT)
Filed by KIORA PHARMACEUTICALS GmbH, Vienna (AT)
Filed on Feb. 22, 2023, as Appl. No. 18/172,656.
Claims priority of provisional application 63/318,281, filed on Mar. 9, 2022.
Prior Publication US 2023/0286938 A1, Sep. 14, 2023
Int. Cl. C07D 333/02 (2006.01)
CPC C07D 333/02 (2013.01) [C07B 2200/13 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A polymorph of 3-(2,3,5,6-tetrafluoro-3′-trifluoromethoxy-biphenyl-4-ylcarbamoyl)-thiophene-2-carboxylic acid as shown in Formula I:

OG Complex Work Unit Chemistry
wherein the polymorph is
Form A comprising an X-ray powder diffraction (XRPD) comprising three or more 2θ values selected from 14.8±0.2, 15.6±0.2, 16.5±0.2, 19.6±0.2, 20.8±0.2, 25.6±0.2 and 26.1±0.2; or
Form B comprising an X-ray powder diffraction (XRPD) comprising three or more 2θ values selected from 14.9±0.2, 17.6±0.2, 19.3±0.2, 20.9±0.2, 24.0±0.2, 24.9±0.2 and 25.4±0.2.